Electromed's direct-to-patient model, broad payer coverage, and disciplined sales execution support durable SmartVest growth. The bronchiectasis market remains substantially underpenetrated, leaving a
Electromed, Inc. (ELMD) Q4 2026 Earnings Call Transcript